CTLA4 and neoplasm: The higher expression of CD274 and CTLA4 in low-risk patients suggests that they may benefit more from immune checkpoint inhibitors, as these molecules help regulate immune response and prevent the release of excessive pro-inflammatory cytokines, thereby potentially limiting tumor progression.